WYLG markedly alleviates pulmonary fibrosis both in vivo and in vitro by inhibiting the TGF-β1/Smad signaling pathway and regulating epithelial-to-mesenchymal transition, highlighting its potential as a therapeutic agent for progressive pulmonary fibrosis.
Zeng et al. (2026) studied this question.